참고문헌
- Agnihotri S, Aldape KD, Zadeh G (2014). Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurg Focus, 37, 13.
- Bleeker FE, Atai NA, Lamba S, et al (2010). The prognostic IDH1 (R132) mutation is associated with reduced NADP+2dependent IDH activity in glioblastoma. Acta Neuropathol, 119, 487-94. https://doi.org/10.1007/s00401-010-0645-6
- Camelo-Piragua S, Jansen M, Ganguly A, et al (2010). Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol, 119, 509-11. https://doi.org/10.1007/s00401-009-0632-y
- Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, et al (2015). Comprehensive, integrative genomic analysis of diffuse lower grade-gliomas. N Engl J Med, 372, 2481-98. https://doi.org/10.1056/NEJMoa1402121
- Capper D, Reuss D, Schittenhelm J, et al (2011). Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma- like morphology. Acta Neuropathol, 121, 241-52. https://doi.org/10.1007/s00401-010-0770-2
- Capper D, Weissert S, Balss J, et al (2010). Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol, 20, 245-54. https://doi.org/10.1111/j.1750-3639.2009.00352.x
- Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009). Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol, 118, 599-01. https://doi.org/10.1007/s00401-009-0595-z
- Chen JR, Yao Y, Xu HZ, Qin ZY (2016). Isocitrate dehydrogenase (idh)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore), 95, 2583. https://doi.org/10.1097/MD.0000000000002583
- Christensen BC, Smith AA, Zheng S, et al (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst, 103, 143-53. https://doi.org/10.1093/jnci/djq497
- Clark O, Yen K, Mellinghoff IK (2016). Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res, 22, 1837-42. https://doi.org/10.1158/1078-0432.CCR-13-1333
- Davis M, Pragani R, Popovici-Muller J, et al (2013). ML309: a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program.
- Eckel-Passow JE, Lachance DH, Molinaro AM, et al (2015). Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med, 372, 2499-508. https://doi.org/10.1056/NEJMoa1407279
- Gravendeel LA, Kouwenhoven MC, Gevaert O, et al (2009). Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res, 69, 9065-72 https://doi.org/10.1158/0008-5472.CAN-09-2307
- Hartmann C, Meyer J, Balss J, et al (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol, 118, 469-74. https://doi.org/10.1007/s00401-009-0561-9
- Hilmani S, Abidi O, Benrahma H, et al (2013). Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients. Mol Neurosci, 49, 567-73. https://doi.org/10.1007/s12031-012-9868-4
- Houillier C, Wang X, Kaloshi G, et al (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurol, 75, 1560-66. https://doi.org/10.1212/WNL.0b013e3181f96282
- Juratli TA, Cahill DP, McCutcheon IE (2015). Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Expert Rev Anticancer Ther, 15, 603-6. https://doi.org/10.1586/14737140.2015.1047351
- Killela PJ, Pirozzi CJ, Healy P, et al (2014). Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 5, 1515-25. https://doi.org/10.18632/oncotarget.1765
- Lee S M, Koh H J, Park DC, et al (2002). Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med, 32, 1185-96. https://doi.org/10.1016/S0891-5849(02)00815-8
- Leeper HE, Caron AA, Decker PA, et al (2015). IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 6, 30295-305. https://doi.org/10.18632/oncotarget.4497
- Leu S, von Felten S, Frank S, Boulay JL, Mariani L (2016). IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. J Neurooncol, 127, 363-72. https://doi.org/10.1007/s11060-015-2048-y
- Li S, Yan C, Huang L, et al (2012). Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol, 14, 109-16. https://doi.org/10.1093/neuonc/nor185
- Louis D N, Ohgaki H, Wiestler OD, Cavenee WK (2007). WHO classification of tumors of the central nervous systems (4th edition). Lyon: International agency for research on cancer (IARC).
- Lv S, Teugels E, Sadones J, et al (2011). Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res, 31, 4457-63.
- Mellai M, Piazzi A, Caldera V, et al (2011). IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol, 105, 345-57. https://doi.org/10.1007/s11060-011-0596-3
- Mukasa A, Takayanagi S, Saito K, et al (2012). Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci, 103, 587-92 https://doi.org/10.1111/j.1349-7006.2011.02175.x
- Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7. https://doi.org/10.1158/1078-0432.CCR-09-0715
- Parsons D W, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
- Patel KP, Ravandi F, Ma D, et al (2011). Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J ClinPathol, 135, 35-45.
- Pellegatta S, Valletta L, Corbetta C, et al (2015). Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun, 3, 4. https://doi.org/10.1186/s40478-014-0180-0
- Pessoa IA, Sagica FE, Anselmo NP, Brito JR, de Oliveira EH (2015). IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil. Genet Mol Res, 14, 6533-42. https://doi.org/10.4238/2015.June.12.6
- Rohle D, Popovici-Muller J, Palaskas N et al. (2013). An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, 340, 626-30. https://doi.org/10.1126/science.1236062
- Sanson M, Marie Y, Paris S, et al (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27, 4150-4. https://doi.org/10.1200/JCO.2009.21.9832
- Schumacher T, Bunse L, Pusch S, et al (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 512, 324-7. https://doi.org/10.1038/nature13387
- Shibahara I, Sonoda Y, Kanamori M, et al (2012). IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol, 17, 551-61. https://doi.org/10.1007/s10147-011-0323-2
- Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the european organization for research and treatment of cancer brain tumor group. Clin Cancer Res, 16, 1597-604. https://doi.org/10.1158/1078-0432.CCR-09-2902
- Waitkus MS, Diplas BH, Yan H (2016). Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol, 18, 16-26. https://doi.org/10.1093/neuonc/nov136
- Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol, 174, 1149-53. https://doi.org/10.2353/ajpath.2009.080958
- Weller M, Felsberg J, Hartmann C, et al (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J Clin Oncol, 27, 5743-50. https://doi.org/10.1200/JCO.2009.23.0805
- Wick W, Hartmann C, Engel C, et al (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol, 27, 5874-80. https://doi.org/10.1200/JCO.2009.23.6497
- Xia L, Wu B, Fu Z, et al (2015). Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget, 6, 17354-65. https://doi.org/10.18632/oncotarget.4008
- Yan H, Parsons DW, Jin G, et al (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360, 765-73. https://doi.org/10.1056/NEJMoa0808710
- Zhang C-B, Bao Z-S, Wang H-J, et al (2014). Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol, 140, 45-51. https://doi.org/10.1007/s00432-013-1519-9
- Zhang RQ, Shi Z, Chen H, et al (2016). Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget, 7, 5030-41. https://doi.org/10.18632/oncotarget.5456